Smith+Nephew (NYSE: SNN) reported second-quarter financial results that included sales growth across its business units.
The London-based orthopedic giant reported yesterday that more than $1.55 billion in sales, marking 7.8% growth over the same period a year ago. Profits of $429 million grew more than 30% from the previous year, with earnings per share coming in at 33¢.
Smith+Nephew reported sequential acceleration across all three of its business units and in all regions. Reconstruction drove Orthopedics growth, while Sports Medicine got a boost from Joint Repair and Arthroscopic Enabling Technologies. The company reported double-digit growth in Advanced Wound Management as well.
For the full year, the company expects revenue growth to reach 5.5%, with a higher cadence of product launches and clinical evidence to spur that improvement. The company still expects a net impact of $15 million to $20 million from tariffs in 2025.
“I’m pleased with our strong performance in the first half of 2025,” said Deepak Nath, Smith+Nephew CEO. “We are delivering sustained higher revenue growth, increased profitability and better cash generation. As expected, revenue growth accelerated in the second quarter, with all regions and business units contributing.
“The operational improvements we have made under the 12-point plan are increasingly translating into better financial performance. We are on track for our full-year revenue growth target, a significant step-up in profitability and strong free-cash generation, and are announcing a $500 million share buyback. There is more to be done, but the transformation of Smith+Nephew is starting to deliver substantial value.”
